Full Text DK-93-01 DIABETES ENDOCRINOLOGY RESEARCH CENTERS NIH GUIDE, Volume 21, Number 35, October 2, 1992 RFA: DK-93-01 P.T. 04 Keywords: Diabetes Endocrinology Metabolism Biomedical Research, Multidiscipl National Institute of Diabetes and Digestive and Kidney Diseases Letter of Intent Receipt Date: December 14, 1992 Application Receipt Date: January 14, 1993 PURPOSE The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for funding of one Diabetes Endocrinology Research Center (DERC) grant to be competitively awarded in Fiscal Year 1994. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Diabetes Endocrinology Research Centers, is related to the priority area of diabetes mellitus. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Minority individuals and women are encouraged to submit as Principal Investigators. Foreign institutions are not eligible to apply. MECHANISM OF SUPPORT Support of this program will be through the National Institutes of Health (NIH) grant-in-aid core center (P30) award. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. In addition to the requirements stated in this announcement, awards will be administered under PHS grants policy as stated in the PHS Grants Policy Statement. FUNDS AVAILABLE The NIDDK anticipates awarding one DERC Grant in Fiscal Year 1994 on a competitive basis. The receipt of one competing continuation application is anticipated, which will be in competition together with the other applications received in response to this announcement. The anticipated award will be for five years and will be contingent upon the availability of appropriated funds. Requests for support must be limited to no more than $750,000 in direct costs per year. Any application exceeding this amount will be returned to the applicant. RESEARCH OBJECTIVES The NIDDK-supported DERCs are part of an integrated program of diabetes-related research support provided by the NIDDK. These Centers have provided a focus for increasing collaboration and cost effectiveness among groups of successful investigators at institutions with established comprehensive diabetes research bases. The objectives of the DERCs are to bring together investigators from relevant disciplines in a manner that will enhance and extend the effectiveness of research related to diabetes and its complications. A Diabetes Center must be an identifiable unit within a single university medical center or a consortium of cooperating institutions, including an affiliated university. The overall goal of the DERC is to bring together, on a cooperative basis, clinical and basic science investigators in a manner that will enrich the effectiveness of diabetes research. An existing program of excellence in biomedical research in the area of diabetes and related metabolic and endocrine disorders is required. This research should be in the form of NIH-funded research projects, program projects, or other peer-reviewed research that is in existence at the time of submission of a Center application. Close cooperation, communication, and collaboration among all involved personnel of all professional disciplines are ultimate objectives. Applicants should consult with NIDDK staff concerning plans for the development of the Center. The DERCs are based on the core concept. Cores are defined as shared resources that enhance productivity or in other ways benefit a group of investigators working in diabetes or diabetes-related areas to accomplish the stated goals of the Center. Two other types of activities may also be supported with Center funding---a pilot and feasibility program and an enrichment program. The pilot and feasibility program provides modest support for new initiatives or feasibility research studies. This program is directed at new investigators or investigators established in other research disciplines, whose expertise may be applied to diabetes research. The center grant may also include limited funds for program enrichment such as seminars, visiting scientists, consultants, and workshops. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. In such a case, a letter of agreement from either the GCRC program director or Principal Investigator should be included with the application. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS It is NIH policy that women and minorities must be included in clinical study populations unless there is a good reason to exclude them. The study design must seek to identify any pertinent gender or minority population differences. NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements are required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis must be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale must be provided. This policy is applicable for every individual study or project proposed in the application. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues must be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information must be included in the form PHS 398 (rev. 9/91) in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, the NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations; i.e., Native Americans (including American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks, Hispanics. The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research is defined as human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis or treatment of diseases, disorders, or conditions including, but not limited to, clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. If the required information is not contained within the application, the application will be returned without review. LETTER OF INTENT Potential applicants are strongly encouraged to submit a letter of intent no later than December 14, 1992. The letter of intent need only include the names of the Principal Investigator/program director and principal collaborators, descriptive title of the potential application, identification of the organization(s) involved, and reference to the RFA number DK-93-01. The letter of intent is to be sent to the Chief, Review Branch, NIDDK at the address noted below. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning the review of applications. It allows NIDDK staff to estimate the potential review workload and to avoid conflict of interest in the review. APPLICATION PROCEDURES Applicants are strongly encouraged to request a copy of "Guidelines for Diabetes Endocrinology Research Centers." These guidelines contain important additional information on the format, content, and review of applications and review criteria. Prospective applicants may obtain guidelines from and may address inquiries to: Dr. Sanford A. Garfield Diabetes Centers Program Director Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 626 Bethesda, MD 20892 Telephone: (301) 496-7418 FAX: (301) 480-0383 Applications are to be submitted on the form PHS 398 (rev. 9/91) available at most institutional business offices and from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 496-7441. On item 2a of the face page of the application, applicants must enter the RFA title and number. The RFA label available in the application form PHS 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application to the extent that it may not reach the review committee in time for review. Applications must be received by January 14, 1993. The original and three copies of the application must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** Two additional copies of the application must be sent under separate cover to: Review Branch National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 603 Bethesda, MD 20892 REVIEW CONSIDERATIONS Upon receipt, applications will be initially reviewed by the Division of Research Grants (DRG) for completeness. Incomplete applications will be returned to the applicant without further consideration. Evaluation of responsiveness to the program requirements and criteria stated in this RFA is an NIDDK staff function. Those applications that are complete and responsive will be evaluated in competition in accordance with the criteria stated below and in the DERC Guidelines for scientific/technical merit by an appropriate peer review group convened by the NIDDK. It is essential that the written application be in a form to be reviewed on its own merit, since no site-visit is anticipated. Following this review, the applications will be given a second level review by the National Diabetes and Digestive and Kidney Diseases Advisory Council. The initial review group will review each application using the criteria stated below: o Scientific excellence of the Center's research base that must have a broad and central focus in diabetes and may extend to related metabolism and endocrinology. The relevance of the separately funded research to the DERC and the likelihood for meaningful collaboration among Center investigators must be demonstrated. o Appropriateness and relevance of the cores and their modes of operation, facilities, and potential for contribution to ongoing research. Renewal applications must include the use, utility, quality control, cost effectiveness, and demonstrated progress of any developmental research in the shared resources. o For new applications, the pilot and feasibility program is judged on the basis of: (1) scientific merit of the studies as submitted and (2) the merit of the administrative process for selecting subsequent studies. In competitive renewal applications, emphasis is accorded to the program as a whole, including past track record and management of the program. o Efficiency and effectiveness of use and/or planned use of enrichment funds. o The scientific and administrative leadership abilities of the DERC Director and Associate Director and their commitment and ability to devote adequate time to the effective management of the DERC program. o The appropriateness of the DERC budgets for the proposed and approved work to be done in core facilities, for pilot and feasibility studies, and for enrichment in relation to the total Center program. o Institutional commitment to the program, including lines of accountability regarding management of the DERC grant and a commitment to establish new positions as necessary. o Enriched academic environment with resources to enable the activities to be conducted. o The institutional commitment to establishing new positions should be presented. o Appropriateness, suitability and integration of research training and other training programs into the overall Center. AWARD CRITERIA Applications will compete for available funds with all other applications submitted in response to this RFA and recommended by peer review. The following will be considered in making funding decisions: o Quality of the proposed Center as determined by peer review o Availability of funds o Overall balance in the DERC program Schedule Letter of Intent Receipt Date: December 14, 1992 Application Receipt Date: January 14, 1993 Initial Review Dates: Jun/Jul 1993 Second Level Review Dates: Sep/Oct 1993 Anticipated Award Date: December 1, 1993 INQUIRIES Written and telephone inquiries concerning this RFA are encouraged. Direct inquiries regarding programmatic issues and requests to: Dr. Sanford A. Garfield Diabetes Centers Program Director Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 626 Bethesda, MD 20892 Telephone: (301) 496-7418 FAX: (301) 480-038 Direct inquiries regarding fiscal matters to: Ms. Linda Stecklein Team Leader and Grants Management Specialist Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 649 Bethesda, MD 20892 Telephone: (301) 496-7467 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.847. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |